Bio/Pharma News

The investment will be used to advance Nemaura’s R&D programs, which include liquid vaccines that have been reformulated for administration through the skin using its micropatch drug delivery technology.

According to results from the FOURIER trial, Repatha significantly reduced the risk of cardiovascular events and death in patients with atherosclerotic cardiovascular disease.

A change in the tax code could help the company create more jobs in the United States, while fewer FDA regulations could help reduce drug prices, according to Pfizer CEO Ian Read.

Novo Nordisk entered a research collaboration with the University of Oxford focused on Type 2 diabetes.

Lek, a Sandoz company, adds capacity to its plant in Prevalje, Slovenia.

Teva said it plans to appeal a district court decision that invalidated several of the company’s Copaxone patents.

Alexandre Juillerat, PhD, innovation senior scientist at Cellectis, discusses novel construct UCART123, an investigational agent that is on deck to be the first gene-edited T-cell product in the United States.

Despite the threat of competition, both from biosimilars to Humira and new therapies that work through other mechanisms of action, AbbVie says Humira is still number one.

ADMA will acquire BPC’s plasma-based fractionation and purification plant in Boca Raton, FL and plans to resolve issues at the facility noted in an FDA warning letter.

The company will gain the rights to a mutein that is believed to help maintain immune system homeostasis.

The companies will split Actellion’s drug discovery and early-stage clinical development assets into a new Swiss biopharmaceutical company.

After a positive Phase II trial, the company said its C. difficile vaccine candidate will advance to Phase III trials during the first half of 2017.

Merck will pay a one-time fee of $625 million and additional royalties to BMS and Ono Pharmaceutical to settle the patent infringement case related to Keytruda.

The company will begin trials with its CBD chewing gum, CanChew Plus, for the treatment of irritable bowel syndrome.

Luke Miels will replace Abbas Mussain as president of GSK’s Global Pharmaceutical division later this year.

The company agreed to pay Forward Pharma $1.25 billion to settle a patent dispute over the formulation of Tecfidera, the company’s leading multiple sclerosis treatment.

An FDA guidance on biosimilar naming garnered mixed responses from the Biosimilars Forum, the American College of Rheumatology, and Pfenex.

Industry experts identify the future focus of the biopharma industry in a new survey.

The membrane-based Protein A purification tool was unveiled at the 2017 PepTalk Conference in San Diego, California.

The company announced that it has terminated an agreement made with UMN Pharma for the co-development of influenza vaccine programs in Japan.

The companies will combine expertise on T-cell therapies with two or more binding domains to create novel oncology medications.

UK-based Orchard Therapeutics and PharmaCell ally to support clinical trials and commercialization of Orchard’s ex-vivo gene therapies.

Takeda will acquire ARIAD Pharmaceuticals for approximately $5.2 billion.

A study of 53 cancer drugs found that new treatments extended patient life an average of 3.43 months when compared with treatments available in 2003.

A judge ruled that Regeneron’s mAb be removed from the market after Amgen alleged that the marketing of Praluent hurt its reputation as innovator of this class of drugs.

Sun Pharma said a fire that left two dead at the company’s Ahmednagar, India factory did not affect production.

PF-06410293 met primary endpoints during clinical trials and demonstrated similar efficacy to its reference product.

J&J’s Innovation Global announced the company has entered into 15 new collaborations.

Prokarium in the UK and Probiomed in Mexico hope to demonstrate large-scale production of oral vaccines that will reduce cost compared to injections and improve availability.

The companies entered into a manufacturing agreement for voclosporin active pharmaceutical ingredient.